Leflunomide

證據等級: L5

預測適應症: 2 個

Leflunomide: Repurposing Candidate — Evaluation On Hold

One-Sentence Summary

Leflunomide is an immunomodulatory disease-modifying antirheumatic drug (DMARD), known in clinical practice for rheumatoid arthritis and psoriatic arthritis treatment. However, the current Evidence Pack contains no TxGNN repurposing predictions for this drug, and key data fields including mechanism of action, safety warnings, and original indication records are absent. Without a predicted indication to evaluate, this report documents the data gaps and recommends a Hold decision pending data remediation.

Quick Overview

Item	Content
Original Indication	Not recorded in current Evidence Pack
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction unavailable; no supporting studies)
Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why No Prediction is Available

The Evidence Pack for Leflunomide (DrugBank ID: DB01097) returned an empty predicted_indications array. Two possible explanations exist:

Pipeline upstream failure: If the drug node for DB01097 was not present or not properly embedded in the knowledge graph used for TxGNN inference, the model would produce no ranked candidates.
Filtered output: Predictions may have been generated but fell below the confidence threshold applied during post-processing.

Until the root cause is confirmed, no repurposing hypothesis can be assessed. The data gaps recorded in the Evidence Pack (DG001: TFDA package insert warnings; DG002: mechanism of action) further limit the safety and mechanistic review that would normally accompany any predicted indication.

Market Information

Leflunomide is not marketed under any current local authorization. The regulatory query returned zero licenses (total_licenses: 0), with no dosage form or approved indication data on file.

Note: The DrugBank query (query log ID 3) and TFDA package insert query (query log ID 4) both returned result_count ≥ 1, indicating source records exist. However, the structured fields in this Evidence Pack were not populated from those results. Remediation should re-extract approved indication text and safety warnings from these confirmed sources.

Safety Considerations

All safety fields in the current Evidence Pack are marked as data gaps:

Key warnings: not available
Contraindications: not available
Drug–drug interactions: query returned no results

Please refer to the package insert and DrugBank record (DB01097) for safety information before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack returned no TxGNN predictions, and the two data gaps rated High/Blocking (MOA and TFDA safety warnings) have not been resolved. There is no repurposing hypothesis to evaluate at this time.

To proceed, the following is needed:

Re-run TxGNN inference for DB01097 and confirm whether the drug node is present in the knowledge graph; if absent, add it and re-embed.
Resolve DG002 (MOA): Query DrugBank API for mechanism of action and pharmacological class data for DB01097.
Resolve DG001 (Safety): Download and parse the TFDA package insert PDF to extract warnings and contraindications; populate key_warnings and contraindications fields.
Re-populate original_indications: The TFDA package insert query (log ID 4) confirmed a result exists — extract the approved indication text and populate the field before the next evaluation cycle.
Once a predicted indication is available, regenerate this report using the full Evidence Pack template.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.